![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
RETRACTION article
Front. Med. , 13 September 2023
Sec. Precision Medicine
Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1292285
This article is part of the Research Topic Radiotheranostics: from Basic Research to Clinical Application View all 6 articles
This article is a retraction of:
RETRACTED: Case Report: Treatment of Hypertrophic Cardiomyopathy With Stereotactic Body Radiotherapy
A Retraction of the Case Report Article
Case report: Treatment of hypertrophic cardiomyopathy with stereotactic body radiotherapy
by Xiao, L., Liu, J., Zhang, Y., Liu, Y., Tang, Y., Zhang, M., Ding, Z., Xiao, E., and Chen, T. (2022). Front. Med. 9:799310. doi: 10.3389/fmed.2022.799310
The journal retracts the 2022 article cited above.
Following publication, concerns were raised regarding the provenance of the patient data used in this study. Specifically, during the investigation, which was conducted in accordance with Frontiers' policies, it was found that the authors failed to provide appropriate authorization for the use of patient data. Unauthorized data use is a breach of Frontiers' guidelines and those of the Committee on Publication Ethics. As such, this article is being retracted.
This retraction was approved by the Chief Editors of Frontiers in Medicine and the Chief Executive Editor of Frontiers. The authors agree to this retraction.
Citation: Frontiers Editorial Office (2023) Retraction: Case report: Treatment of hypertrophic cardiomyopathy with stereotactic body radiotherapy. Front. Med. 10:1292285. doi: 10.3389/fmed.2023.1292285
Received: 11 September 2023; Accepted: 11 September 2023;
Published: 13 September 2023.
Approved by:
Alice Chen, Consultant, Potomac, MD, United StatesCopyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.